DUBLIN, April 19, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Multiple Myeloma Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Velcade, Revlimid and Emerging Supplementary Treatments" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO )
Without any treatment, the median survival of a myeloma patient is about six months, but this can be extended with the use of various forms of treatment. There are now five classes of drugs used in the treatment of myeloma: immunomodulatory drugs, chemotherapy, proteasome drugs, Histone Deacetylase (HDAC) inhibitors and steroids. Many of the notable drugs in these classes were approved over the past 10-15 years.
Treatment using these novel drugs and high-dose chemotherapy with hematopoietic Stem-Cell Transplant (SCT) has been shown to improve median survival to five years, which makes this the current standard therapy. However, many patients suffer relapse or develop treatment resistance, leaving a need to develop safe and effective treatments that prolong the duration of remission and improve survival.
Scope
The different segments of patients with MM are based on their eligibility for an SCT
- What combination therapies are used for various segments?
- What are the treatment options available for myeloma, providing an overview of the front-line, second-line and third-line therapies available?
There are seven main marketed products for MM, with most of the novel drugs being approved in the last decade.
- What are the dominant mechanisms of action across marketed products?
- Which products are approved currently in each country and which ones are likely to be launched within the forecast period?
- Which product is used more in each country?
- Will there be any label expansions of existing market leaders in any of the countries?
Epidemiology of MM is significantly different in Asia-Pacific countries from that in the major markets.
- What are the various epidemiology trends in each country?
- What factors contribute to the overall epidemiology?
The MM pipeline consists of more than 250 products in active development. Small molecules are the most abundant molecule type in the pipeline, accounting for 48% of all products.
- What are the various pipeline products based on molecule type, mechanism of action and stage of development?
- Which class is most prominent within the pipeline?
- Do the pipeline molecules offer an advantage over commercially proven mechanisms?
- What are the late-pipeline products expected to be launched in each country in the near future?
Analysis of clinical trials since 2006 identified that MM products have a high rate of attrition.
- How do failure rates vary by product stage of development, molecule type, and mechanism of action?
- How do other factors such as average trial duration and trial size influence the costs and risks associated with product development?
- What are the current promising pipeline drugs and their efficacy data?
Over the 2014-2020 forecast period, the MM market in Australia, China, India and Japan is expected to increase in value at a CAGR of 7.4%, from $1.7 billion to about $2.8 billion.
- Which markets make the most significant contribution to the current market size?
- What are the incidence, diagnosis and treatment trends in these markets?
- What are the factors responsible for difference in the treatment patterns within the four markets?
- Which factors will influence growth rates?
- Will new market entrants lead to substantial changes in annual therapy costs?
Some key marketed products are expected to expire in the forecast period, and promising pipeline molecules are likely to be launched in the near future.
- Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?
- Will the patent expiration be offset by the approval of new therapies?
Key Topics Covered:
1 Tables & Figures
2 Introduction
3 Marketed Products
4 Pipeline Products
5 Clinical Trials
6 Market Forecast to 2021
7 Drivers and Barriers for the Disease Market
8 Deals and Strategic Consolidations
9 Appendix
For more information visit http://www.researchandmarkets.com/research/sdzdnx/multiple_myeloma
Media Contact:
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Share this article